Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Carboplatin + Cediranib + Paclitaxel lung cancer no benefit detail...
ERBB2 mutant Neratinib lung cancer sensitive detail...
Unknown unknown Nintedanib lung cancer not applicable detail...
PIK3CA H1047R BEZ235 lung cancer sensitive detail...
PIK3CA H1047R Sirolimus lung cancer no benefit detail...
EML4 - ALK ALK G1202R Lorlatinib lung cancer conflicting detail...
FGFR1 amp Brivanib lung cancer no benefit detail...
Unknown unknown Cediranib + Gefitinib lung cancer not applicable detail...
Unknown unknown SNG12 lung cancer not applicable detail...
Unknown unknown TAK-960 lung cancer not applicable detail...
STK11 loss unspecified PD-1 antibody lung cancer resistant detail...
EML4 - ALK SRC pos Repotrectinib lung cancer sensitive detail...
EML4 - ALK SRC pos Crizotinib lung cancer resistant detail...
Unknown unknown HD105 lung cancer not applicable detail...
Unknown unknown AZD7762 + Berzosertib lung cancer not applicable detail...
Unknown unknown ABTL0812 lung cancer not applicable detail...
FGFR1 amp AZD4547 lung cancer sensitive detail...
FGFR1 wild-type AZD4547 lung cancer decreased response detail...
ERBB2 Y772_A775dup Afatinib lung cancer sensitive detail...
ERBB2 G776delinsVC Afatinib lung cancer sensitive detail...
ERBB2 G776delinsLC Afatinib lung cancer sensitive detail...
ERBB2 G778_P780dup Afatinib lung cancer sensitive detail...
ERBB2 Y772_A775dup Gefitinib lung cancer no benefit detail...
ERBB2 G776delinsVC Gefitinib lung cancer no benefit detail...
ERBB2 G776delinsLC Gefitinib lung cancer no benefit detail...
ERBB2 G778_P780dup Gefitinib lung cancer no benefit detail...
ERBB2 V659E Gefitinib lung cancer no benefit detail...
ERBB2 G660D Gefitinib lung cancer no benefit detail...
ERBB2 V659E Afatinib lung cancer sensitive detail...
ERBB2 G660D Afatinib lung cancer sensitive detail...
NOTCH1 positive LY3039478 lung cancer sensitive detail...
ERBB2 T798I Lapatinib lung cancer resistant detail...
Unknown unknown CBP501 + Cisplatin lung cancer not applicable detail...
Unknown unknown Apatinib lung cancer not applicable detail...
Unknown unknown PU-H71 lung cancer not applicable detail...
Unknown unknown Dinaciclib + Paclitaxel lung cancer not applicable detail...
Unknown unknown ABT-737 + Perifosine lung cancer not applicable detail...
Unknown unknown Metformin lung cancer not applicable detail...
CDKN2A del PF-00477736 + PF3644022 lung cancer predicted - sensitive detail...
Unknown unknown CT16 lung cancer not applicable detail...
EML4 - ALK X-376 lung cancer sensitive detail...
Unknown unknown TC-A2317 lung cancer not applicable detail...
Unknown unknown AZ628 + Trametinib lung cancer not applicable detail...
FGFR1 amp Erdafitinib lung cancer predicted - sensitive detail...
FGFR1 amp GSK3052230 lung cancer sensitive detail...
BRAF V600E Ulixertinib lung cancer sensitive detail...
BRAF L597Q Ulixertinib lung cancer sensitive detail...
U2AF1 S34F H3B-8800 lung cancer sensitive detail...
Unknown unknown Triolimus lung cancer not applicable detail...
CTNNB1 T41A NTRC 0066-0 lung cancer predicted - sensitive detail...
CTNNB1 T41A Mps-BAY2b lung cancer predicted - sensitive detail...
CTNNB1 T41A NMS-P715 lung cancer predicted - sensitive detail...
CTNNB1 T41A BAY1161909 lung cancer predicted - sensitive detail...
CTNNB1 T41A BAY1217389 lung cancer predicted - sensitive detail...
CTNNB1 T41A Mps1-IN-1 lung cancer predicted - sensitive detail...
CTNNB1 T41A MPI-0479605 lung cancer predicted - sensitive detail...
Unknown unknown Camrelizumab lung cancer not applicable detail...
NRAS Q61K RAF709 lung cancer sensitive detail...
ATM positive AZD1390 lung cancer sensitive detail...
ERBB2 Y772_A775dup Poziotinib lung cancer sensitive detail...
AKT1 S266L FGFR1 amp PD173074 lung cancer predicted - resistant detail...
FGFR1 amp PD173074 lung cancer sensitive detail...
AKT1 S266L FGFR1 amp Uprosertib lung cancer predicted - sensitive detail...
BRAF G469A RMC-4550 lung cancer resistant detail...
BRAF G466V RMC-4550 lung cancer predicted - sensitive detail...
Unknown unknown Capmatinib lung cancer not applicable detail...
ERBB2 amp TAS0728 lung cancer predicted - sensitive detail...
Unknown unknown VB-111 lung cancer not applicable detail...
PDGFRA amp Ripretinib lung cancer sensitive detail...
Unknown unknown OBI-999 lung cancer not applicable detail...
Unknown unknown BOS172722 lung cancer not applicable detail...
ERBB2 amp Lapatinib lung cancer sensitive detail...
Unknown unknown CAB-AXL-ADC lung cancer not applicable detail...
Unknown unknown JNJ-64619178 lung cancer not applicable detail...
Unknown unknown SKI-G-801 lung cancer not applicable detail...
EML4 - ALK ALK L1152R Ceritinib lung cancer resistant detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01014598 Phase I Cisplatin Cisplatin in Treating Patients With Lung Cancer Completed
NCT01218867 Phase Ib/II Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes Terminated
NCT01366144 Phase I Paclitaxel Veliparib Carboplatin Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Active, not recruiting
NCT01386580 Phase Ib/II 2B3-101 2B3-101 + Trastuzumab An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. Completed
NCT01470209 Phase I Buparlisib + Everolimus A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies Completed
NCT01859026 Phase I Binimetinib + Erlotinib A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation Active, not recruiting
NCT01935336 Phase II Ponatinib Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers Active, not recruiting
NCT01999985 Phase I Afatinib + Dasatinib Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) Completed
NCT02047747 Phase II Dacomitinib A Phase II Study of Dacomitinib in Progressive Brain Metastases Terminated
NCT02155465 Phase Ib/II Erlotinib + Ruxolitinib Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib Completed
NCT02241369 Phase I INO-3106 + INO-9012 Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies Completed
NCT02264236 Phase Ib/II Montanide ISA 51 + P10s-PADRE Vaccination of Advanced-Stage Lung Cancer Patients Recruiting
NCT02310464 Phase I OBI-821 + OBI-833 Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects Recruiting
NCT02429843 Phase I Carboplatin + Paclitaxel Bevacizumab Carotuximab A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer Active, not recruiting
NCT02433626 Phase I COTI-2 Cisplatin + COTI-2 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) Recruiting
NCT02538627 Phase I Seribantumab MM-151 Phase 1 Combination Study of MM-151 and MM-121 Terminated
NCT02675829 Phase II Ado-trastuzumab emtansine Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers Active, not recruiting
NCT03188965 Phase I BAY1895344 First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas Recruiting
NCT03199586 Phase I NP-G2-044 Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) Recruiting
NCT03373760 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer Recruiting
NCT03477162 Phase 0 Metformin Metformin Pharmacology in Human Cancers: A Proof of Principle Study Recruiting
NCT03597009 Phase Ib/II Nivolumab + Talimogene laherparepvec A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion Recruiting
NCT03719768 Phase I Avelumab Avelumab With Radiotherapy in Patients With Leptomeningeal Disease Recruiting
NCT04085315 Phase I Alisertib + Osimertinib Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer Recruiting
NCT04148937 Phase I LY3475070 LY3475070 + Pembrolizumab A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer Recruiting
NCT04259450 Phase Ib/II AFM24 Study to Assess AFM24 in Advanced Solid Cancers Recruiting
NCT04273061 Phase II Atezolizumab Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity (CAPTIV-8) Not yet recruiting
NCT04287868 Phase Ib/II M7824 + NHS-IL12 + PDS0101 Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies Not yet recruiting